Stealth BioTherapeutics Announces FDA Advisory Committee Meeting to Review Elamipretide for Barth Syndrome Treatment

Meeting Scheduled with Cardiovascular and Renal Drugs Advisory Committee on October 10, 2024 NEEDHAM, Mass., Sept. 9, 2024 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage biotechnology company focused on the discovery, development and…